Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Mechanism TSLPR inhibitors(cytokine receptor like factor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ph-Like Acute Lymphoblastic Leukemia | Preclinical | AU | 26 Oct 2023 |